Drug Profile
Anti-CD8-idarubicin conjugate
Alternative Names: Anti-Ly-2.1-idarubicin conjugateLatest Information Update: 06 Aug 2002
Price :
$50
*
At a glance
- Originator Unknown
- Class Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Transplant rejection